Compare Incyte Corporation (INCY) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs NIO Inc. — how do they compare? Incyte Corporation trades at $117 (market cap $23.11B), while NIO Inc. trades at $4.81 (market cap $12.55B). The key difference: Incyte Corporation is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| INCY | NIO | |
|---|---|---|
Market Cap | $23.11B | $12.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $118.52 | $7.89 |
52-Week Low | $67.38 | $4.44 |
Enterprise Value | $19.13B | $11.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $117.39, up 0.12% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $112.78. The company reported strong Q1 2026 earnings of $1.81 per share, beating expectations, and maintains robust profitability with a net income margin of 26.71%. Recent developments include a collaboration with Halozyme for cancer therapy and positive regulatory updates for Opzelura in Europe.
Outlook remains positive driven by earnings growth and pipeline advancements, though risks include competitive pressures and reliance on key products. The stock offers potential upside to the high target of $140, supported by institutional interest and solid cash flow generation, but investors should monitor execution on upcoming Q2 results.
NIO trades at $4.79, down 1.84% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though it remains unprofitable with negative cash flow. Analyst sentiment is mixed with 54% buy ratings but technical indicators show selling pressure. Recent vehicle deliveries surged 62.9% year-over-year in June 2026, providing optimism for margin improvement.
NIO presents a high-risk opportunity with significant growth potential but persistent profitability challenges. The stock offers exposure to China's EV market expansion but faces execution risks and competitive pressures. While delivery momentum is strong, investors must weigh the company's cash burn against its market position and Goldman Sachs' recent upgrade to buy with $7 target.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
